| 3.62 -0.08 (-2.16%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.09  |
1-year : | 7.28 |
| Resists | First : | 5.21 |
Second : | 6.23 |
| Pivot price | 4.73 |
|||
| Supports | First : | 3.56 | Second : | 2.97 |
| MAs | MA(5) : | 3.82 |
MA(20) : | 4.89 |
| MA(100) : | 6.48  |
MA(250) : | 4.67 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 14.7 |
| RSI | RSI(14): 28 |
|||
| 52-week | High : | 9.23 | Low : | 2.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SGHT ] has closed above bottom band by 12.3%. Bollinger Bands are 47.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.69 | 3.69 - 3.71 |
| Low: | 3.52 - 3.56 | 3.56 - 3.58 |
| Close: | 3.58 - 3.63 | 3.63 - 3.66 |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Wed, 11 Mar 2026
Sight Sciences (SGHT) Q4 2025 Earnings Transcript - AOL.com
Mon, 09 Mar 2026
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 earnings call transcript - MSN
Sat, 07 Mar 2026
Sight Sciences Earnings Call Highlights Disciplined Growth - TipRanks
Fri, 06 Mar 2026
Sight Sciences Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Fri, 06 Mar 2026
Sight Sciences (NASDAQ:SGHT) Price Target Cut to $11.00 by Analysts at UBS Group - MarketBeat
Fri, 06 Mar 2026
Sight Sciences (SGHT) EPS Loss Narrows Again And Tests Bearish Profitability Narratives - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 53 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 52.9 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 1,160 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | -49.7 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -50.8 % |
| Qtrly Rev. Growth | 6.9 % |
| Gross Profit (p.s.) | 1.26 |
| Sales Per Share | 1.46 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -4.03 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 2.47 |
| Price to Cash Flow | -6.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|